Carregant...
Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab
BACKGROUND: Nivolumab is approved for the treatment of advanced renal cell carcinoma (RCC). However, traditional overall survival (OS) or progression-free survival (PFS) do not reflect patient prognosis after initial management. Therefore, this study aimed to evaluate conditional overall survival (C...
Guardat en:
| Publicat a: | Med Sci Monit |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
International Scientific Literature, Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6738006/ https://ncbi.nlm.nih.gov/pubmed/31469816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.916984 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|